Holen Sie sich die Stockscreener-App
0.7952
5.32%
-0.0447
Schlusskurs vom Vortag:
$0.8399
Offen:
$0.85
24-Stunden-Volumen:
559.43K
Relative Volume:
0.67
Marktkapitalisierung:
$100.04M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.91M
KGV:
-3.6145
EPS:
-0.22
Netto-Cashflow:
$-19.57M
1W Leistung:
-4.22%
1M Leistung:
-8.59%
6M Leistung:
-42.79%
1J Leistung:
-21.27%
1-Tages-Spanne:
$0.7901
$0.85
1-Wochen-Bereich:
$0.7901
$0.885
52-Wochen-Spanne:
$0.7203
$2.31
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Firmenname
Atossa Therapeutics Inc
Sektor
Branche
Telefon
206.588.0256
Adresse
10202 5TH AVENUE NE, SEATTLE, WA
Vergleichen Sie ATOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.7952 | 100.04M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-01-26 | Eingeleitet | Maxim Group | Buy |
Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Up 5.8% in January - MarketBeat
Atossa Therapeutics reports progress in breast cancer treatments - MSN
Atossa Therapeutics Inc (ATOS) looking to reclaim success with recent performance - SETE News
Atossa Therapeutics (NASDAQ:ATOS) Stock Crosses Below 200 Day Moving AverageHere's Why - MarketBeat
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Bought by SG Americas Securities LLC - Defense World
Market Watch Highlights: Atossa Therapeutics Inc (ATOS) Ends on an Downturn Note at 0.77 - The Dwinnex
Investing in Atossa Therapeutics Inc (ATOS) Is Getting More Attractive - Knox Daily
Atossa Therapeutics faces patent setback, continues development - MSN
FY2029 Earnings Forecast for ATOS Issued By HC Wainwright - MarketBeat
What is HC Wainwright's Estimate for ATOS FY2029 Earnings? - MarketBeat
Atossa Therapeutics Congratulates Board Director Dr. Tessa - GlobeNewswire
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care - The Manila Times
Major CDC Grant Fuels Revolutionary Breast Cancer Care Program in NYC - StockTitan
Do investors need to be concerned about Atossa Therapeutics Inc (ATOS)? - US Post News
Financial Metrics Unveiled: Atossa Therapeutics Inc (ATOS)’s Key Ratios in the Spotlight - The Dwinnex
Equities Analysts Set Expectations for ATOS FY2029 Earnings - Defense World
Atossa Therapeutics (NASDAQ:ATOS) Given "Buy" Rating at HC Wainwright - MarketBeat
JPMorgan Chase & Co. Acquires 95,643 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
HC Wainwright Reiterates Buy Rating for Atossa Therapeutics (NASDAQ:ATOS) - Defense World
Atossa Genetics stock hits 52-week low at $0.75 - MSN
Atossa Genetics stock hits 52-week low at $0.75 By Investing.com - Investing.com Australia
Atossa Therapeutics Will Not Appeal PTAB Decision on Review of Patent Covering Endoxifen - Marketscreener.com
Troy Minerals Inc. (TROY-CN) QuotePress Release - The Globe and Mail
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent - GlobeNewswire
Atossa's Patent Strategy Shift: New Endoxifen Patent Reinforces 118+ Protected Claims - StockTitan
Option Volatility And Earnings Report For January 2731 - The Globe and Mail
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 - The Manila Times
Atossa Therapeutics reports progress in breast cancer treatments By Investing.com - Investing.com South Africa
Atossa's Endoxifen Shows Breakthrough 23.5% Breast Density Reduction in Phase 2 Cancer Trial - StockTitan
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Stake Raised by Barclays PLC - Defense World
Jane Street Group LLC Trims Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics (NASDAQ: ATOS) vs. NLS Pharmaceutics (NASDAQ: NLSP): A Comparative Analysis - HPBL
Head-To-Head Analysis: Atossa Therapeutics (NASDAQ:ATOS) & NLS Pharmaceutics (NASDAQ:NLSP) - Defense World
The Hidden Connection: Dr. Steven Quay on Alcohol and Cancer Risk - Cville Right Now
Atossa Therapeutics Applauds U.S. Surgeon General’s - GlobeNewswire
Surgeon General Links Alcohol to 44,000 Annual Breast Cancer Cases, Atossa Backs Warning - StockTitan
Geode Capital Management LLC Has $4.28 Million Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Barclays PLC Has $255,000 Stock Holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
State Street Corp Has $2.63 Million Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Sees Large Decrease in Short Interest - MarketBeat
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by XTX Topco Ltd - Defense World
Finanzdaten der Atossa Therapeutics Inc-Aktie (ATOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):